The Restrictive Red Blood Cell Transfusion Strategy for Critically Injured Patients (RESTRIC) trial: a cluster-randomized, crossover, non-inferiority multicenter trial of restrictive transfusion in trauma
Primary result · 28-day survivalResult — go to the resultAOR for 28-day survival 1.02 95% CI 0.49–2.13Authors' conclusion
Although non-inferiority of the restrictive versus liberal transfusion strategy for 28-day survival was not statistically significant, the mortality and complication rates were similar between the groups. The restrictive transfusion strategy results in a lower transfusion volume.
Study context
- Population
- Adults with severe trauma at risk of major bleeding, 22 tertiary emergency medical institutions in Japan22 institutions
- Participants
- 216 vs 195
- Comparison
- Restrictive vs liberal RBC transfusion strategy
- Restrictiven = 216
- Liberaln = 195reference
- Primary endpoint
- Survival after arrival at the ED
- Follow-up
- 28 days
Methodological detailscluster-randomized, crossover, non-inferiority, multicenter
- Cluster-randomized
- Crossover
- Non-inferiority
- Multicenter
Primary result
28-day survival
AOR for 28-day survival
1.02
95% CI 0.49–2.13
By group
Restrictive vs Liberal
aOR for 28-day survival 1.02 (95% CI 0.49–2.13)
Non-inferiority margin 3 as printed, not drawn
As reported in the abstract
Secondary outcomes
Transfusion volume and hemoglobin levels
- Lower in the restrictive than the liberal group
Event-free days
- No between-group differences
Safety
Complication rates
- No between-group differences
Original publication
The Restrictive Red Blood Cell Transfusion Strategy for Critically Injured Patients (RESTRIC) trial: a cluster-randomized, crossover, non-inferiority multicenter trial of restrictive transfusion in trauma. J Intensive Care. Published 24 July 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →